9 research outputs found

    Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes.

    Get PDF
    OBJECTIVE: Proinsulin is a precursor of mature insulin and C-peptide. Higher circulating proinsulin levels are associated with impaired β-cell function, raised glucose levels, insulin resistance, and type 2 diabetes (T2D). Studies of the insulin processing pathway could provide new insights about T2D pathophysiology. RESEARCH DESIGN AND METHODS: We have conducted a meta-analysis of genome-wide association tests of ∼2.5 million genotyped or imputed single nucleotide polymorphisms (SNPs) and fasting proinsulin levels in 10,701 nondiabetic adults of European ancestry, with follow-up of 23 loci in up to 16,378 individuals, using additive genetic models adjusted for age, sex, fasting insulin, and study-specific covariates. RESULTS: Nine SNPs at eight loci were associated with proinsulin levels (P < 5 × 10(-8)). Two loci (LARP6 and SGSM2) have not been previously related to metabolic traits, one (MADD) has been associated with fasting glucose, one (PCSK1) has been implicated in obesity, and four (TCF7L2, SLC30A8, VPS13C/C2CD4A/B, and ARAP1, formerly CENTD2) increase T2D risk. The proinsulin-raising allele of ARAP1 was associated with a lower fasting glucose (P = 1.7 × 10(-4)), improved β-cell function (P = 1.1 × 10(-5)), and lower risk of T2D (odds ratio 0.88; P = 7.8 × 10(-6)). Notably, PCSK1 encodes the protein prohormone convertase 1/3, the first enzyme in the insulin processing pathway. A genotype score composed of the nine proinsulin-raising alleles was not associated with coronary disease in two large case-control datasets. CONCLUSIONS: We have identified nine genetic variants associated with fasting proinsulin. Our findings illuminate the biology underlying glucose homeostasis and T2D development in humans and argue against a direct role of proinsulin in coronary artery disease pathogenesis

    OPLS-DA score plot showing a partial separation between patients with bipolar disorder I (top panel), bipolar disorder II (middle panel) and healthy controls (lower panel).

    No full text
    <p>Each participant’s score is represented by a circle. The scores were t[<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0115562#pone.0115562.ref001" target="_blank">1</a>] values on the component predictive of diagnostic group. The vast majority (97%) of the participants were within a ±2 standard deviation limit according to Hotelling’s T<sup>2</sup>. Positive values represent better overall performance.</p

    Performance of euthymic patients with bipolar disorder I (BD I), bipolar disorder II (BD II), and healthy controls (C) on a neuropsychological test battery.

    No full text
    <p>The neuropsychological measures are arranged according to the size of the OPLS-DA loadings. Results are expressed as means, 95% confidence intervals (CIs) and effect sizes (<i>η</i><sup>2</sup>). Percentage was calculated of patients scoring ≤ the 1.25 s.d. of the control group.</p><p><i>Note.</i></p><p><sup>a</sup> Pålsson et al, 2012,</p><p><sup>b</sup> loading on predictive component,</p><p><sup>c</sup> Games Howell otherwise Scheffé.</p><p>Performance of euthymic patients with bipolar disorder I (BD I), bipolar disorder II (BD II), and healthy controls (C) on a neuropsychological test battery.</p

    Summary of demographic and clinical characteristics in patients with bipolar disorder I (n = 64) and bipolar disorder II (n = 44).

    No full text
    <p>The controls (n = 86) were matched for age and sex (X% female). No differences were found regarding education level between the bipolar disorder groups and the control group.</p><p><sup>a</sup> data from 47–64 patients</p><p><sup>b</sup> data from 36–44 patients</p><p>Summary of demographic and clinical characteristics in patients with bipolar disorder I (n = 64) and bipolar disorder II (n = 44).</p

    Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index

    Get PDF
    Obesity is globally prevalent and highly heritable, but its underlying genetic factors remain largely elusive. To identify genetic loci for obesity susceptibility, we examined associations between body mass index and similar to 2.8 million SNPs in up to 123,865 individuals with targeted follow up of 42 SNPs in up to 125,931 additional individuals. We confirmed 14 known obesity susceptibility loci and identified 18 new loci associated with body mass index (P < 5 x 10(-8)), one of which includes a copy number variant near GPRC5B. Some loci (at MC4R, POMC, SH2B1 and BDNF) map near key hypothalamic regulators of energy balance, and one of these loci is near GIPR, an incretin receptor. Furthermore, genes in other newly associated loci may provide new insights into human body weight regulation

    Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes

    Get PDF
    OBJECTIVE - Proinsulin is a precursor of mature insulin and C-peptide. Higher circulating proinsulin levels are associated with impaired b-cell function, raised glucose levels, insulin resistance, and type 2 diabetes (T2D). Studies of the insulin processing pathway could provide new insights about T2D pathophysiology. RESEARCH DESIGN AND METHODS - We have conducted a meta-analysis of genome-wide association tests of ;2.5 million genotyped or imputed single nucleotide polymorphisms (SNPs) and fasting proinsulin levels in 10,701 nondiabetic adults of European ancestry, with follow-up of 23 loci in up to 16,378 individuals, using additive genetic models adjusted for age, sex, fasting insulin, and study-specific covariates. RESULTS - Nine SNPs at eight loci were associated with proinsulin levels (P < 5 × 10-8). Two loci (LARP6 and SGSM2) have not been previously related to metabolic traits, one (MADD) has been associated with fasting glucose, one (PCSK1) has been implicated in obesity, and four (TCF7L2, SLC30A8, VPS13C/ C2CD4A/B, and ARAP1, formerly CENTD2) increase T2D risk. The proinsulin-raising allele of ARAP1 was associated with a lower fasting glucose (P = 1.7 3 10-4), improved b-cell function (P = 1.1 × 10-5), and lower risk of T2D (odds ratio 0.88; P = 7.8 × 10-6). Notably, PCSK1 encodes the protein prohormone convertase 1/3, the first enzyme in the insulin processing pathway. A genotype score composed of the nine proinsulin-raising alleles was not associated with coronary disease in two large case-control datasets. CONCLUSIONS - We have identified nine genetic variants associated with fasting proinsulin. Our findings illuminate the biology underlying glucose homeostasis and T2D development in humans and argue against a direct role of proinsulin in coronary artery disease pathogenesis
    corecore